Literature DB >> 15811373

Atomic resolution structures of CTX-M beta-lactamases: extended spectrum activities from increased mobility and decreased stability.

Yu Chen1, Julien Delmas, Jacques Sirot, Brian Shoichet, Richard Bonnet.   

Abstract

Extended spectrum beta-lactamases (ESBLs) confer bacterial resistance to third-generation cephalosporins, such as cefotaxime and ceftazidime, increasing hospital mortality rates. Whereas these antibiotics are almost impervious to classic beta-lactamases, such as TEM-1, ESBLs have one to four orders greater activity against them. The origins of this activity have been widely studied for the TEM and SHV-type ESBLs, but have received less attention for the CTX-M beta-lactamases, an emerging family that is now the dominant ESBL in several regions. To understand how CTX-M beta-lactamases achieve their remarkable activity, biophysical and structural studies were undertaken. Using reversible, two-state thermal denaturation, it was found that as these enzymes evolve a broader substrate range, they sacrifice stability. Thus, the mutant enzyme CTX-M-16 is eightfold more active against ceftazidime than the pseudo-wild-type CTX-M-14 but is 1.9 kcal/mol less stable. This is consistent with a "stability-activity tradeoff," similar to that observed in the evolution of other resistance enzymes. To investigate the structural basis of enzyme activity and stability, the structures of four CTX-M enzymes were determined by X-ray crystallography. The structures of CTX-M-14, CTX-M-27, CTX-M-9 and CTX-M-16 were determined to 1.10 Angstroms, 1.20 Angstroms, 0.98 Angstroms and 1.74 Angstroms resolution, respectively. The enzyme active sites resemble those of the narrow-spectrum TEM-1 and SHV-1, and not the enlarged sites typical of ESBL mutants such as TEM-52 and TEM-64. Instead, point substitutions leading to specific interactions may be responsible for the improved activity against ceftazidime and cefotaxime, consistent with observations first made for the related Toho-1 enzyme. The broadened substrate range of CTX-M-16 may result from coupled defects in the enzyme's B3 strand, which lines the active site. Substitutions Val231-->Ala and Asp240-->Gly, which convert CTX-M-14 into CTX-M-16, occur at either end of this strand. These defects appear to increase the mobility of B3 based on anisotropic B-factor analyses at ultrahigh resolution, consistent with stability loss and activity gain. The unusually high resolution of these structures that makes such analyses possible also makes them good templates for inhibitor discovery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15811373     DOI: 10.1016/j.jmb.2005.02.010

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  68 in total

1.  Noncovalent complexes of an inactive mutant of CTX-M-9 with the substrate piperacillin and the corresponding product.

Authors:  David Leyssene; Julien Delmas; Frédéric Robin; Antony Cougnoux; Lucie Gibold; Richard Bonnet
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.

Authors:  Akiko Shimizu-Ibuka; Mika Oishi; Shoko Yamada; Yoshikazu Ishii; Kiyoshi Mura; Hiroshi Sakai; Hiroshi Matsuzawa
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

3.  Crystal structures of covalent complexes of β-lactam antibiotics with Escherichia coli penicillin-binding protein 5: toward an understanding of antibiotic specificity.

Authors:  George Nicola; Joshua Tomberg; R F Pratt; Robert A Nicholas; Christopher Davies
Journal:  Biochemistry       Date:  2010-09-21       Impact factor: 3.162

4.  Co-evolution of affinity and stability of grafted amyloid-motif domain antibodies.

Authors:  Mark C Julian; Christine C Lee; Kathryn E Tiller; Lilia A Rabia; Evan K Day; Arthur J Schick; Peter M Tessier
Journal:  Protein Eng Des Sel       Date:  2015-09-19       Impact factor: 1.650

5.  Unexpected enzyme TEM-126: role of mutation Asp179Glu.

Authors:  J Delmas; F Robin; F Bittar; C Chanal; R Bonnet
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

6.  CMT-type beta-lactamase TEM-125, an emerging problem for extended-spectrum beta-lactamase detection.

Authors:  Frédéric Robin; Julien Delmas; Maryse Archambaud; Cédric Schweitzer; Catherine Chanal; Richard Bonnet
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

7.  Prediction of the evolution of ceftazidime resistance in extended-spectrum beta-lactamase CTX-M-9.

Authors:  J Delmas; F Robin; F Carvalho; C Mongaret; R Bonnet
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

8.  The acylation mechanism of CTX-M beta-lactamase at 0.88 a resolution.

Authors:  Yu Chen; Richard Bonnet; Brian K Shoichet
Journal:  J Am Chem Soc       Date:  2007-04-05       Impact factor: 15.419

9.  Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.

Authors:  Frédéric Robin; Julien Delmas; Cédric Schweitzer; Olivier Tournilhac; Olivier Lesens; Catherine Chanal; Richard Bonnet
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

10.  The Drug-Resistant Variant P167S Expands the Substrate Profile of CTX-M β-Lactamases for Oxyimino-Cephalosporin Antibiotics by Enlarging the Active Site upon Acylation.

Authors:  Meha P Patel; Liya Hu; Vlatko Stojanoski; Banumathi Sankaran; B V Venkataram Prasad; Timothy Palzkill
Journal:  Biochemistry       Date:  2017-06-27       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.